Metastatic Lung Cancer: When Lung Cancer Spreads

Key Takeaways

• Metastatic lung cancer — also called Stage IV lung cancer — means the cancer has spread beyond the lung to distant organs or lymph nodes.

• The most common sites of spread include the brain, bones, liver, and adrenal glands, each producing its own set of symptoms.

• Biomarker testing (EGFR, ALK, KRAS, PD-L1, and others) is essential at diagnosis because the results directly determine which treatments are most likely to work.

• Advances in targeted therapy and immunotherapy have significantly improved survival for many patients — some people with EGFR-mutated metastatic NSCLC now live three to four years or longer with treatment.

• Clinical trial participation offers access to emerging treatments and is a legitimate option worth discussing with your care team from the start.

What Is Metastatic Lung Cancer?

Metastatic lung cancer means the cancer that started in the lung has spread to other parts of the body, such as the brain, bones, liver, or adrenal glands. This is also called Stage IV lung cancer. In some cases, cancer involving certain distant or contralateral lymph node groups is classified as Stage IIIB.

It’s important to understand one key distinction: metastatic lung cancer refers specifically to a cancer that originated in the lung and then traveled elsewhere. This is different from lung metastases, which is where cancer from another organ, such as the breast or colon, spreads to the lung. These two situations are treated very differently, because treatment is always based on where the cancer began.

When lung cancer cells break away from the original tumor, they can enter the bloodstream or lymphatic system and travel to distant sites, where they settle and form new tumors called metastases. Because these distant tumors are made of lung cancer cells, not cells from the new location like liver cells or brain cells, they are still treated with lung cancer treatments.

Where Does Lung Cancer Spread?

Lung cancer can spread to virtually any organ, but some sites are far more common than others. Knowing where the cancer has spread helps guide treatment decisions and shapes what symptoms you might experience.

Brain

Brain metastases occur in an estimated 30–50% of NSCLC patients over the course of their disease, according to data from multiple large studies. In adenocarcinoma specifically, one large analysis found a 30.2% overall incidence of brain metastases. Symptoms can include persistent headaches, dizziness, changes in memory or concentration, weakness on one side of the body, vision disturbances, and, less commonly, seizures. Some brain metastases are found on routine staging scans before any symptoms develop.

Bone

Bone metastases affect approximately 22% of NSCLC patients, most commonly involving the spine, ribs, pelvis, and long bones of the arms and legs. Symptoms include deep, aching bone pain that may be worse at night, and an increased risk of fractures — including spinal fractures that can press on the spinal cord. Spinal cord compression is a medical emergency requiring urgent treatment. Medications called bone-protecting agents like bisphosphonates (such as zoledronic acid) and denosumab are used to reduce the risk of fractures and bone-related complications.

Liver

Liver involvement is another common site, particularly in small cell lung cancer. Symptoms can include abdominal pain or discomfort in the upper right side of the abdomen, jaundice (yellowing of the skin or eyes), nausea, and fatigue. In many cases, especially early on, liver metastases are found on imaging before causing noticeable symptoms, and elevated liver enzyme levels on blood tests may be the first sign.

Adrenal Glands

The adrenal glands, which sit above the kidneys, are a frequent site of spread in lung cancer. Adrenal metastases are often asymptomatic and discovered incidentally on CT scans during staging. In most cases, adrenal involvement alone does not significantly affect hormone function, though it does confirm Stage IV disease.

Other Sites

Lung cancer can also spread to other areas of the lung, to distant lymph nodes, to the lining around the lung (pleura), and less commonly to the kidneys, skin, and other organs. Pleural involvement can cause a buildup of fluid around the lung called a pleural effusion, which may produce shortness of breath, a dry cough, and discomfort.

Symptoms of Metastatic Lung Cancer

Metastatic lung cancer produces symptoms from two sources: the original tumor in the lung, and the sites where the cancer has spread.

Lung-related symptoms often include a persistent cough, coughing up blood, shortness of breath, chest pain, and hoarseness. You can read more about the full range of symptoms on our lung cancer symptoms page.

Symptoms related to metastatic sites depend on where the cancer has spread:

• Brain metastases: headaches, cognitive changes, vision problems, personality changes, weakness or numbness

• Bone metastases: localized bone pain, tenderness, increased fracture risk, back pain that may indicate spinal involvement

• Liver metastases: right-sided abdominal discomfort, nausea, jaundice, swelling in the abdomen

• Adrenal metastases: usually no symptoms initially

Systemic symptoms that are common across all metastatic lung cancer, regardless of site, include profound fatigue, unintentional weight loss, loss of appetite, and a general sense of feeling unwell.

Two less common but important syndromes worth knowing:

• Superior vena cava (SVC) syndrome: If a tumor presses on the large vein that returns blood from the upper body to the heart, it can cause swelling of the face, neck, and arms, along with difficulty breathing and a sense of fullness in the head. This requires prompt evaluation.

• Pancoast tumor symptoms: Tumors at the very top of the lung (the apex) can compress nerves in the shoulder, causing shoulder and arm pain, weakness in the hand, and Horner’s syndrome (drooping eyelid, small pupil, and absence of sweating on one side of the face).

How Metastatic Lung Cancer Is Diagnosed

If you’ve already been diagnosed with lung cancer, metastatic spread may be discovered during routine staging — a process that uses imaging to determine whether cancer has moved beyond the chest. If new symptoms develop during or after treatment, additional imaging is used to check for progression.

Staging imaging typically includes:

• CT scan of the chest, abdomen, and pelvis — the standard first step for assessing spread to the liver, adrenal glands, and lymph nodes

• PET scan — uses a radioactive tracer to highlight areas of high metabolic activity, which can reveal metastatic disease not yet visible on CT

• Brain MRI — standard for all patients with newly diagnosed NSCLC, since brain metastases are common and may be missed on CT

If the original site of cancer is unknown, a biopsy of a metastatic site may be taken to determine the cancer type and origin.

Biomarker testing is one of the most critical steps in diagnosing metastatic lung cancer — and it should happen at every patient’s initial workup. Comprehensive testing for mutations including EGFR, ALK, KRAS G12C, ROS1, BRAF, MET, RET, NTRK, and HER2, as well as PD-L1 expression, is now standard of care for advanced NSCLC. These results directly determine which treatments are most effective and should not be skipped. Next-generation sequencing (NGS) of tumor tissue, supplemented in some cases by liquid biopsy (circulating tumor DNA from blood), is the recommended approach.

Learn more about the diagnostic process on our lung cancer diagnosis page and about how staging is determined on our lung cancer stages page.

Treatment Options for Metastatic Lung Cancer

Metastatic lung cancer is typically not curable, but that does not mean treatment cannot make a meaningful difference. The goals of treatment are to control the cancer, relieve symptoms, maintain quality of life, and extend life — sometimes significantly, depending on the cancer’s molecular profile and your overall health. Advances over the past decade have transformed what’s possible for many patients.

Biomarker-Driven Targeted Therapy

For patients whose tumors carry certain genetic mutations, targeted therapy — drugs designed to attack specific molecular drivers — can be highly effective even at Stage IV.

• EGFR mutations (present in about 15% of NSCLC patients in the U.S., and up to 40–50% in Asian populations): Osimertinib (Tagrisso) is the preferred first-line treatment, often combined with platinum-based chemotherapy based on the FLAURA2 trial. These oral medications can be taken at home.

• ALK rearrangements (approximately 5% of NSCLC): Alectinib is a preferred first-line option, with data showing a median progression-free survival of 35 months versus 11 months for older treatments.

• KRAS G12C mutations (approximately 13% of NSCLC): Sotorasib and adagrasib have received FDA approval for patients who have progressed on prior therapy.

• Other actionable mutations — ROS1, BRAF V600E, MET exon 14, RET, NTRK, HER2 — each have approved or guideline-recommended targeted treatments.

Immunotherapy

For patients whose tumors express high levels of PD-L1 and who do not have a targetable mutation, immunotherapy — specifically checkpoint inhibitors that release the immune system’s brakes — has become a cornerstone of treatment. Pembrolizumab (Keytruda) is approved as monotherapy for patients with PD-L1 tumor proportion score of 50% or greater, or in combination with chemotherapy for a broader population. Atezolizumab, nivolumab, and cemiplimab are also used in various settings. For patients with extensive-stage small cell lung cancer, durvalumab and atezolizumab have been added to chemotherapy regimens.

Chemotherapy

Platinum-based chemotherapy — typically carboplatin or cisplatin combined with pemetrexed (for non-squamous NSCLC) or paclitaxel — remains an important option, particularly when combined with immunotherapy or targeted agents. For patients with SCLC, etoposide-based regimens are standard.

Radiation Therapy

Radiation plays an important role in managing specific metastatic complications:

• Brain metastases: Stereotactic radiosurgery (SRS) can precisely target individual brain metastases with minimal damage to surrounding tissue; whole-brain radiation therapy (WBRT) is used in selected cases.

• Bone metastases: Palliative radiation can effectively relieve pain and reduce fracture risk.

• Spinal cord compression: Radiation (often with steroids) is used urgently to prevent or limit neurological damage.

Managing Specific Complications

Beyond systemic therapy, targeted interventions address specific metastatic problems: bone-protecting agents (bisphosphonates and denosumab) for bone metastases; intrathecal chemotherapy for leptomeningeal disease; and in selected patients with a single or very limited number of metastases (oligometastatic disease), surgical resection or ablative therapy may be considered.

Clinical Trials

Clinical trial participation is not a last resort — it is a legitimate treatment option worth discussing early in your care. Active trials are investigating bispecific antibodies, antibody-drug conjugates (ADCs), novel checkpoint inhibitors, and combinations of targeted agents for virtually every molecular subtype of lung cancer. Participating in a trial may give you access to treatments not yet widely available while contributing to advances that will help future patients. Explore options on our lung cancer clinical trials page.

Learn more about the full range of treatment approaches on our lung cancer treatment page.

Prognosis and What to Expect

Prognosis for metastatic lung cancer has changed substantially over the past decade, and statistics that are even a few years old may no longer reflect what’s achievable today. That said, it’s important to be honest: Stage IV lung cancer remains serious, and survival statistics are population-level averages — they cannot predict what will happen for any individual person.

What current data shows:

• According to SEER data, the 5-year relative survival rate for distant-stage (Stage IV) lung cancer is approximately 8–9% overall. However, this figure includes many patients diagnosed before modern immunotherapy and targeted therapy became standard.

• A study published in 2024 found that between 2010–2013 and 2018–2020, median survival for Stage IV NSCLC increased by 53.7% — from 6.7 months to 10.3 months — driven largely by the shift from chemotherapy to immunotherapy.

• For patients with EGFR-mutated NSCLC treated with osimertinib plus chemotherapy, the FLAURA2 trial (results published in the New England Journal of Medicine in 2025) reported a median overall survival of 47.5 months — the longest median OS reported in a global Phase III trial for this population.

• For patients with high PD-L1 expression (≥50%) treated with pembrolizumab monotherapy, the KEYNOTE-024 trial’s 5-year update found an overall survival rate of 31.9% — meaning nearly one in three patients was alive five years after starting treatment, compared to 16.3% with chemotherapy.

Factors that influence individual outcomes include the specific mutation driving the cancer, how well the tumor responds to treatment, the number and location of metastases, your overall health and performance status, and access to comprehensive cancer care.

Goals of care at Stage IV are centered on controlling the disease for as long as possible, managing symptoms effectively, and maintaining the best possible quality of life. Palliative care — specialized support focused on symptom management and quality of life — is not the same as giving up. Evidence consistently shows that patients who receive palliative care alongside cancer treatment feel better, manage symptoms more effectively, and in some studies live longer. Many people benefit from discussing goals of care and advance care planning early, while there is time to make thoughtful decisions.

For more on survival data, visit our lung cancer survival rates page.

Living With Metastatic Lung Cancer

A metastatic lung cancer diagnosis changes everything and navigating life with this disease takes practical support, honest information, and a strong care team. Here is what can help:

Managing symptoms and side effects — Work closely with your oncologist and palliative care team to address pain, fatigue, breathing difficulties, and treatment side effects. Many symptoms can be effectively managed, and doing so significantly improves quality of life.

Mental and emotional health — Anxiety, depression, and fear are common and understandable responses to this diagnosis. Counseling, support groups (in person or online), and peer support programs connect you with others who truly understand what you are facing. Ask your care team for a referral to an oncology social worker or psychologist.

Caregiver support — Family members and caregivers carry a significant burden. Organizations like the Lung Cancer Research Foundation and the American Lung Association offer resources specifically for caregivers.

Advance care planning — Having conversations about your values, preferences, and goals with your medical team and loved ones helps ensure your care reflects what matters most to you, at every stage of the journey.

Clinical trial participation — Joining a trial is one way to access treatments still under investigation, contribute to research, and potentially benefit from the next generation of lung cancer therapies. Ask your oncologist whether there are trials appropriate for your specific cancer type and mutation profile.

Clinical trials have driven major advances in metastatic lung cancer treatment — and new options are actively being studied. Ready to explore trials that may be right for you? Start your search with North’s trial finder.

Frequently Asked Questions

What does it mean when lung cancer is metastatic?

Metastatic lung cancer means the cancer that originated in the lung has spread to other organs or distant lymph nodes. This is classified as Stage IV lung cancer (or Stage IIIB in some cases involving specific lymph node involvement). The cancer cells at the new location are still lung cancer cells — not cells native to the organ where they’ve settled — which is why treatment is based on the cancer’s lung cancer characteristics, including its molecular profile.

What is the life expectancy for metastatic lung cancer?

Life expectancy varies widely depending on several factors, including the cancer’s molecular subtype, overall health, and treatment response. Population-level data show a median survival of roughly 10–14 months for Stage IV NSCLC overall, but this average conceals a wide range of individual outcomes. Patients with EGFR-mutated NSCLC treated with osimertinib plus chemotherapy achieved a median overall survival of 47.5 months in the FLAURA2 trial. Patients with high PD-L1 expression treated with pembrolizumab had a 5-year survival rate of nearly 32% in the KEYNOTE-024 trial. These results show that for patients with favorable molecular profiles and effective treatment, long-term survival is achievable.

Can metastatic lung cancer be treated?

Yes. While metastatic lung cancer is typically not curable, it can often be effectively treated. Targeted therapies, immunotherapy, chemotherapy, and radiation — alone or in combination — can control the cancer, relieve symptoms, and extend life. The right treatment depends on the cancer’s biomarker profile, which is why comprehensive molecular testing at diagnosis is so important. Clinical trials offer access to additional options, including investigational therapies not yet widely available.

What is the most common place lung cancer spreads to?

The most common sites where lung cancer spreads include the brain, bones, liver, and adrenal glands. Brain metastases develop in an estimated 30–50% of NSCLC patients over the course of their disease. Bone metastases affect approximately 22% of NSCLC patients. The liver and adrenal glands are also frequent sites of spread, often detected on imaging before causing symptoms.

References

1. Reck, M., Rodríguez-Abreu, D., Robinson, A. G., et al. (2021). Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%. Journal of Clinical Oncology, 39(21), 2339–2349. https://doi.org/10.1200/JCO.21.00174

2. Planchard, D., Jänne, P. A., Cheng, Y., et al. (2025). Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2510308

3. Baena-Espinar, J., Yuan, Z., Fakhri, B., et al. (2024). Recent survival gains in stage IV NSCLC by sociodemographic strata. PMC/NCBI. https://pmc.ncbi.nlm.nih.gov/articles/PMC11985032/

4. Morgensztern, D., Waqar, S., Subramanian, J., et al. (2016). Prognostic value of site-specific metastases in lung cancer: a population-based study. Journal of Cancer, 10, 3079–3086. https://www.jcancer.org/v10p3079.htm

5. Mehta, M., Khan, A., Danish, S., et al. (2023). Risk and prognostic factors of brain metastasis in lung cancer patients: a SEER population-based cohort study. PMC/NCBI. https://pmc.ncbi.nlm.nih.gov/articles/PMC10373853/

6. National Cancer Institute. (2025). Cancer of the lung and bronchus — cancer stat facts. SEER. https://seer.cancer.gov/statfacts/html/lungb.html

7. Huang, Z., et al. (2024). Development of brain metastases in non-small-cell lung cancer: high-risk features. Lung Cancer: Targets and Therapy, 15, 97–110. https://pmc.ncbi.nlm.nih.gov/articles/PMC11404603/